Published in Clin Infect Dis on January 01, 2009
OR PathTrac (Tracking Intra-operative Bacterial Transmission) | NCT03605498
Reducing Perioperative S. Aureus Transmission | NCT03638947
Tobramycin Administered at the Beginning of Dialysis (ESRD) | NCT03904836
Reducing Intraoperative Infection Transmission in the Pediatric Operating Room | NCT03992209
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis (2010) 35.92
Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev (2010) 7.35
Hospital-acquired infections due to gram-negative bacteria. N Engl J Med (2010) 6.61
Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis (2011) 5.58
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis (2013) 4.07
The shared antibiotic resistome of soil bacteria and human pathogens. Science (2012) 3.98
Platforms for antibiotic discovery. Nat Rev Drug Discov (2013) 3.66
Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature (2010) 3.58
Non-prescription antimicrobial use worldwide: a systematic review. Lancet Infect Dis (2011) 3.54
Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med (2011) 3.20
Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action. Antimicrob Resist Infect Control (2012) 3.02
Novel classes of antibiotics or more of the same? Br J Pharmacol (2011) 2.99
High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis (2012) 2.92
Pseudomonas aeruginosa: resistance to the max. Front Microbiol (2011) 2.76
Using matrix-assisted laser desorption ionization-time of flight mass spectrometry to detect carbapenem resistance within 1 to 2.5 hours. J Clin Microbiol (2011) 2.59
Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med (2011) 2.16
Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother (2009) 2.12
Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med (2012) 2.09
Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature (2015) 2.04
Engineering Streptomyces coelicolor for heterologous expression of secondary metabolite gene clusters. Microb Biotechnol (2010) 2.02
Bacterial phylogeny structures soil resistomes across habitats. Nature (2014) 1.98
Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother (2010) 1.94
Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother (2010) 1.89
A call for action: the application of The International Health Regulations to the global threat of antimicrobial resistance. PLoS Med (2011) 1.88
Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother (2009) 1.83
Colistin administration to pediatric and neonatal patients. Eur J Pediatr (2010) 1.83
Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother (2012) 1.78
ESBLs: A Clear and Present Danger? Crit Care Res Pract (2011) 1.77
Understanding the determinants of antimicrobial prescribing within hospitals: the role of "prescribing etiquette". Clin Infect Dis (2013) 1.74
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother (2010) 1.68
Fresh approaches to anti-infective therapies. Sci Transl Med (2012) 1.67
Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob Agents Chemother (2010) 1.62
The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect Immun (2010) 1.61
Complete sequence of a novel 178-kilobase plasmid carrying bla(NDM-1) in a Providencia stuartii strain isolated in Afghanistan. Antimicrob Agents Chemother (2012) 1.60
Antimicrobial resistance: the major contribution of poor governance and corruption to this growing problem. PLoS One (2015) 1.59
New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob (2013) 1.58
The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care (2011) 1.58
Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant (2013) 1.58
Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections. Crit Care (2010) 1.57
Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. Antimicrob Agents Chemother (2012) 1.55
Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). World J Emerg Surg (2016) 1.55
Nosocomial bloodstream infections in Brazilian hospitals: analysis of 2,563 cases from a prospective nationwide surveillance study. J Clin Microbiol (2011) 1.54
Complete sequencing of the bla(NDM-1)-positive IncA/C plasmid from Escherichia coli ST38 isolate suggests a possible origin from plant pathogens. PLoS One (2011) 1.53
Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res (2010) 1.52
Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge. Antimicrob Agents Chemother (2009) 1.51
Reducing uncertainty in managing respiratory tract infections in primary care. Br J Gen Pract (2010) 1.50
Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother (2013) 1.50
In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother (2011) 1.50
Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother (2013) 1.49
Metagenomic analysis of apple orchard soil reveals antibiotic resistance genes encoding predicted bifunctional proteins. Appl Environ Microbiol (2010) 1.49
Frequent multidrug-resistant Acinetobacter baumannii contamination of gloves, gowns, and hands of healthcare workers. Infect Control Hosp Epidemiol (2010) 1.47
Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother (2010) 1.46
When the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transition. PLoS Biol (2013) 1.45
Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol (2010) 1.45
Detection of Alpha-Toxin and Other Virulence Factors in Biofilms of Staphylococcus aureus on Polystyrene and a Human Epidermal Model. PLoS One (2016) 1.45
Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother (2013) 1.44
A Chemical-Genomic Screen of Neglected Antibiotics Reveals Illicit Transport of Kasugamycin and Blasticidin S. PLoS Genet (2016) 1.43
fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother (2010) 1.42
Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis (2015) 1.42
Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother (2012) 1.41
In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother (2013) 1.41
Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem (2014) 1.41
Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One (2012) 1.40
Ecology and evolution as targets: the need for novel eco-evo drugs and strategies to fight antibiotic resistance. Antimicrob Agents Chemother (2011) 1.40
Methicillin resistance in Staphylococcus aureus requires glycosylated wall teichoic acids. Proc Natl Acad Sci U S A (2012) 1.39
Genomic insights to control the emergence of vancomycin-resistant enterococci. MBio (2013) 1.37
Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Respir Med (2014) 1.36
Daptomycin-resistant Enterococcus faecalis diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids. MBio (2013) 1.35
Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother (2011) 1.32
Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med (2014) 1.31
Klebsiella variicola is a frequent cause of bloodstream infection in the stockholm area, and associated with higher mortality compared to K. pneumoniae. PLoS One (2014) 1.30
Enterobacter aerogenes and Enterobacter cloacae; versatile bacterial pathogens confronting antibiotic treatment. Front Microbiol (2015) 1.29
Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to β-lactams. ACS Chem Biol (2012) 1.29
Developmental dynamics of the preterm infant gut microbiota and antibiotic resistome. Nat Microbiol (2016) 1.29
The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2012) 1.27
Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother (2010) 1.27
Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother (2011) 1.26
A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level β-lactam resistance contains mutations in three genes. Antimicrob Agents Chemother (2010) 1.26
AB5075, a Highly Virulent Isolate of Acinetobacter baumannii, as a Model Strain for the Evaluation of Pathogenesis and Antimicrobial Treatments. MBio (2014) 1.26
The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother (2012) 1.25
A new pharmacological agent (AKB-4924) stabilizes hypoxia inducible factor-1 (HIF-1) and increases skin innate defenses against bacterial infection. J Mol Med (Berl) (2012) 1.24
Aminoglycoside resistance and susceptibility testing errors in Acinetobacter baumannii-calcoaceticus complex. J Clin Microbiol (2010) 1.23
Design and synthesis of C-2 substituted thiazolo and dihydrothiazolo ring-fused 2-pyridones: pilicides with increased antivirulence activity. J Med Chem (2010) 1.22
Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit. Clin Infect Dis (2011) 1.22
Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med (2014) 1.21
Dosing of colistin-back to basic PK/PD. Curr Opin Pharmacol (2011) 1.20
Impact of patient satisfaction ratings on physicians and clinical care. Patient Prefer Adherence (2014) 1.20
Contact precautions for multidrug-resistant organisms: Current recommendations and actual practice. Am J Infect Control (2009) 1.20
Bad bugs, no drugs: no ESCAPE revisited. Clin Infect Dis (2009) 1.20
Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res (2010) 1.20
Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control (2014) 1.20
Reversible antibiotic tolerance induced in Staphylococcus aureus by concurrent drug exposure. MBio (2015) 1.19
Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother (2014) 1.19
Systems-level antimicrobial drug and drug synergy discovery. Nat Chem Biol (2013) 1.19
IMP-producing carbapenem-resistant Klebsiella pneumoniae in the United States. J Clin Microbiol (2011) 1.19
Adaptation of Enterococcus faecalis to daptomycin reveals an ordered progression to resistance. Antimicrob Agents Chemother (2013) 1.18
D-enantiomeric peptides that eradicate wild-type and multidrug-resistant biofilms and protect against lethal Pseudomonas aeruginosa infections. Chem Biol (2015) 1.17
Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother (2014) 1.17
Newer antibacterial drugs for a new century. Expert Opin Investig Drugs (2010) 1.16
Structure and biosynthesis of the antibiotic bottromycin D. Org Lett (2012) 1.16
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis (2008) 9.57
Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis (2005) 8.77
Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med (2005) 8.39
Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis (2010) 6.59
Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59
Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2009) 6.52
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis (2011) 5.58
Guidelines for treatment of candidiasis. Clin Infect Dis (2003) 5.55
Trends in antimicrobial drug development: implications for the future. Clin Infect Dis (2004) 5.23
Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis (2008) 5.05
Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med (2014) 5.05
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med (2004) 4.75
A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis (2003) 4.29
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis (2013) 4.07
Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases. Antimicrob Agents Chemother (2003) 3.92
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother (2009) 3.82
Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis (2004) 3.75
Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics (2004) 3.71
Comparative analysis of the activity and content of different streptokinase preparations. Eur Heart J (2005) 3.65
Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS Pathog (2006) 3.58
Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol (2007) 3.43
Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med (2008) 3.36
Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis (2004) 3.35
Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog (2009) 3.05
Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol (2007) 3.02
Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway. Mol Microbiol (2002) 3.01
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis (2003) 2.92
A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis (2003) 2.84
Functional and structural diversity in the Als protein family of Candida albicans. J Biol Chem (2004) 2.77
Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt) (2010) 2.67
Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis (2008) 2.63
Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother (2005) 2.54
The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest (2007) 2.48
Mice with disseminated candidiasis die of progressive sepsis. J Infect Dis (2005) 2.42
The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier. Sci Signal (2010) 2.40
Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob Res (2004) 2.34
Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis (2005) 2.28
Current treatment strategies for disseminated candidiasis. Clin Infect Dis (2005) 2.25
Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2004) 2.23
Oral acyclovir suppression and neurodevelopment after neonatal herpes. N Engl J Med (2011) 2.18
A novel peptidoglycan cross-linking enzyme for a beta-lactam-resistant transpeptidation pathway. J Biol Chem (2005) 2.18
Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis (2007) 2.17
Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio (2012) 2.15
Pathogenesis of mucormycosis. Clin Infect Dis (2012) 2.14
In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother (2009) 2.12
Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics (2002) 2.08
Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother (2003) 2.01
Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother (2006) 1.99
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother (2008) 1.96
Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J Infect Dis (2010) 1.96
the hyphal-associated adhesin and invasin Als3 of Candida albicans mediates iron acquisition from host ferritin. PLoS Pathog (2008) 1.94
Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis (2010) 1.92
Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother (2005) 1.90
Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J (2013) 1.90
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob Agents Chemother (2008) 1.89
Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes. Antimicrob Agents Chemother (2005) 1.88
Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials. Clin Infect Dis (2009) 1.83
Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis (2010) 1.78
Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis. Infect Immun (2003) 1.78
The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun (2008) 1.77
Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children. Pediatrics (2010) 1.77
NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine (2012) 1.77
Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis (2011) 1.72
Dr. William H. Stewart: mistaken or maligned? Clin Infect Dis (2008) 1.71
FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother (2011) 1.68
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother (2010) 1.67
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother (2011) 1.66
A community-based outbreak of severe respiratory illness caused by human adenovirus serotype 14. J Infect Dis (2009) 1.66
Recurrent systemic pneumococcal disease in children. Pediatr Infect Dis J (2007) 1.65
Severe acute malnutrition in childhood: hormonal and metabolic status at presentation, response to treatment, and predictors of mortality. J Clin Endocrinol Metab (2014) 1.64
Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis (2006) 1.64
Seven ways to preserve the miracle of antibiotics. Clin Infect Dis (2013) 1.63
Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob Agents Chemother (2010) 1.62
Relationship between Candida albicans virulence during experimental hematogenously disseminated infection and endothelial cell damage in vitro. Infect Immun (2004) 1.59
Intrinsic and acquired resistance mechanisms in enterococcus. Virulence (2012) 1.59
Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin. Antimicrob Agents Chemother (2004) 1.58
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother (2010) 1.58
When kinases meet mathematics: the systems biology of MAPK signalling. FEBS Lett (2005) 1.56
Evaluation of a commercial microarray system for detection of SHV-, TEM-, CTX-M-, and KPC-type beta-lactamase genes in Gram-negative isolates. J Clin Microbiol (2010) 1.55
Use of denaturing gradient gel electrophoresis for analysis of the stool microbiota of hospitalized patients. J Microbiol Methods (2003) 1.54
The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect Immun (2005) 1.53
Comparative study of the use of computer assisted navigation system for axial correction in medial unicompartmental knee arthroplasty. Knee Surg Sports Traumatol Arthrosc (2008) 1.53
Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J (2013) 1.52
Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J (2004) 1.52
A review of the science regarding dental unit waterlines. J Am Dent Assoc (2002) 1.51
Cotransfer of antibiotic resistance genes and a hylEfm-containing virulence plasmid in Enterococcus faecium. Antimicrob Agents Chemother (2009) 1.51